Table 2

Cell marker biomarkers identified in the literature search (with some selected references)

Sepsis Marker

Evaluated in experimental studies

Evaluated in clinical studies

Evaluated as a prognostic factor

Comment


CD10 [80,81]

A

Decreased in septic shock compared with healthy controls

CD11b [82,83]

B(s)

Correlation with SOFA score

CD11c [84]

A

Decreased in septic shock compared with healthy controls

CD14 (cellular and soluble) [85]

C

Distinguished between survivors and non-survivors at 28 days

CD18 [86]

CD25 (cellular and soluble) [87]

A

Distinguished between survivors and non-survivors at 28 days

CD28 (soluble) [88]

B

Distinguished between survivors and non-survivors at 28 days

CD40 (cellular and soluble) [89]

B

Distinguished between survivors and non-survivors at 28 days

CD48 [90]

B

Increased in sepsis compared with healthy controls

CD64 [91]

B

Correlation with APACHE II and SOFA scores

CD69 [92]

A

Increased in sepsis compared with healthy controls

CD80 [88]

B

Predicted development of septic shock

CD163 (soluble) [93]

C

Distinguished between survivors and non-survivors at 28 days

mHLA-DR (soluble) [94]

C

√*

Distinguished between survivors and non-survivors at 28 days in patients with septic shock


*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only.

APACHE: acute physiology and chronic health evaluation; SOFA: sequential organ failure assessment.

Pierrakos and Vincent Critical Care 2010 14:R15   doi:10.1186/cc8872

Open Data